Clinical Trial

Arginine Metabolism in Youth With Type 2 Diabetes

Completed
View on ClinicalTrials.gov →
Summary
Type 2 diabetes (T2D), once considered only "a disease of older ages," is now a significant public health concern in youth. Although it is characterized by insulin resistance and impaired insulin secretion, its precise etiology and pathogenesis are not yet fully understood. This study aims to (1) explore arginine metabolism in youth with T2D via safe, minimally invasive kinetic experiments using stable isotope tracers and targeted metabolomics, and (2) determine the effect of exogenous arginine administration on β-cell function in youth with T2D, potentially supporting the use of this safe, low-cost, and readily available nutrient to improve pediatric diabetes outcomes.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-14
notable Primary completion moved earlier: 2027-06-30 -> 2026-06-18 2026-08-14
minor Completion moved earlier: 2027-08-31 -> 2026-06-18 2026-08-14
Trial Details
NCT Number NCT05477134
Lead Sponsor Baylor College of Medicine
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Type 2 Diabetes
Enrollment 30 participants
Start Date 2023-02-06
Primary Completion 2026-06-18 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-13